[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Morocco\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":514},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,45,71,106,137,164,195,220,258,282,310,331,361,384,415,441,461,491],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100644598","dietary-supplements-among-cancer-patients-tolerance-impact-on-medications-and-potential-drug-interactions-100644598",false,"NCT07670234","Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions","Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software","Dietary Supple","Inclusion Criteria:\n\n* Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.\n* Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).\n* Adult patients : \\>=18\n\nExclusion Criteria:\n\n* Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.\n* Failure or refusal to provide written informed consent.","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.\n\nThe main questions it aims to answer :\n\n* What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?\n* Are there any potential drug interactions between dietary supplements and anticancer medications?\n\nParticipants will:\n\n* Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.\n* Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).\n* Report any perceived adverse effects related to dietary supplement use to assess tolerance.\n* Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.",[26,27],"Cancer (Solid Tumors)","Interaction Drug Food",[29,30,31],"dietary supplements","cancer","Anticancer Therapy","RECRUITING","2026-06-19",{"date":35,"type":36},"2026-06-26","ACTUAL",{"date":38,"type":36},"2025-06-01",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100597965","a-multicenter-observational-study-to-understand-the-clinical-characteristics-treatment-patterns-and-access-to-novel-therapies-of-patients-with-diffuse-large-b-cell-lymphoma-in-the-mea-region-100597965","NCT07065344","A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region","A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region A Cross-sectional Multi-center, Observational Study to Describe the Disease Characteristics and Treatment Patterns and Explore Access to Novel Therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Both Treatment naïve and Relapsed\u002FRefractory Patients in the Middle East & Africa (MEA) Region.","DOMAIN","Inclusion Criteria:\n\n1. Male or female patients aged 18 years or older at diagnosis.\n2. Patients who have confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) according to the investigator's decision and\u002For histopathological diagnosis.\n3. For Cohort 1: DLBCL patients who are eligible to start treatment\\* according to the investigator's decision.\n4. For Cohort 2: patients who are diagnosed with DLBCL and have failed at least one prior line of therapy.\n5. Patients willing to sign the written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation.\n\nExclusion Criteria:\n\n1. Patients who are not eligible for treatment for any reason, according to the investigator's judgment and decision\n2. Patients with concurrent active malignancies other than DLBCL.\n3. Patients who are actively participating in any other clinical trial.",{"count":54,"type":21},500,"Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with over 80,500 estimated new cases diagnosed in the United States in 20231. Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of NHL, accounting for 30%-40% of cases2. DLBCL is an aggressive malignancy with heterogeneous biology and behavior. Disease risk stratification and treatment planning involve various patient and clinical characteristics (e.g., age, stage, and tumor bulk), prognostic indices (e.g., International Prognostic Index (IPI) score), and gene expression profiling. Patients typically present with nodal or extranodal disease, usually exhibiting rapid tumor growth and symptoms that are highly dependent upon the tumor localization.\n\nThe diagnosis and subtyping of DLBCL have significantly advanced, from morphological assessment of tissue slide to numerous ancillary tests, including immunophenotyping performed by immunohistochemistry (IHC), cytogenetics, and detailed molecular testing to classify the disease based on cell of origin (COO). With the advent of novel therapeutic options, molecular subtyping of DLBCL at diagnosis is expected to allow prognostic stratification of patients into distinct subgroups. This stratification could provide a preclinical rationale for therapeutic targeting the involved pathways and paving the application of personalized treatment.\n\nDLBCL is a potentially curable disease with an overall 60-70% chance of achieving durable complete remission (CR) with the currently used standard first-line immunochemotherapy. However, 30-40% of patients are either refractory to first-line treatment or experience relapse and eventually will die of disease progression7. Although high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is the recommended SOC for eligible patients in the second-line setting based on results from the pivotal PARMA study, real-world SOC in this setting remains less clearly defined.\n\nPatients not cured with ASCT or ineligible to ASCT or refractory to salvage chemotherapy may be considered for Chimeric Antigen Receptor (CAR) T cell therapy targeting CD1910. Although ASCT and CAR-T cell therapy offer patients an opportunity for durable remission, many patients may not be eligible for ASCT or CAR-T cell therapy or relapse after these treatments. In the last decade, the investigation of novel antigens, which can be targeted by immunotherapy and identified to eliminate malignant cells regardless of their molecular pathogenesis, has been constantly pursued.\n\nThis study aims to address this need by examining the demographic, clinical characteristics, and treatment patterns and exploring access to novel therapies for diffuse large B-cell lymphoma (DLBCL) patients, both treatment naïve and relapsed\u002Frefractory patients, in the Middle East and Africa (MEA) region.",[57,58],"Hematology","Diffused Large B Cell Lymphoma",[58],"2026-06-17",{"date":62,"type":36},"2026-06-18",{"date":64,"type":36},"2025-07-23",{"date":66,"type":21},"2027-01-31",{"name":68,"class":69},"AstraZeneca","INDUSTRY",21,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100621465","effect-of-clinical-hypnosis-in-preoperative-anxiety-among-patients-undergoing-an-abdominal-surgery-100621465","NCT07370974","Effect of Clinical Hypnosis in Preoperative Anxiety Among Patients Undergoing an Abdominal Surgery.","Effect of Clinical Hypnosis in Preoperative Anxiety Among Patients Undergoing an Abdominal Surgery : a Multicenter Randomized Controlled Trial.","Hypnoanxiety","* Inclusion Criteria:\n\n  1. Consenting patients undergoing abdominal surgery\n  2. ASA I-II physical status\n  3. Able to understand and respond to instructions\n  4. No major psychological disorders\n* Exclusion Criteria:\n\n  1. Non-consenting patients\n  2. Prior experience with hypnosis\n  3. History of mental illness\n  4. Psychoactive substance consumption\n  5. Cognitive disorders","80 Years",{"count":81,"type":21},48,"INTERVENTIONAL",[84],"NA","This Multicenter randomized controlled trial evaluates clinical hypnosis efficacy for reducing perioperative anxiety and postoperative pain in abdominal surgery patients across 3 Moroccan centers (n=48-68). Intervention arm receives 15-20 min level 2 hypnosis session preoperatively; control receives standard psychological preparation. Primary outcome: VAS-anxiety post-intervention. Secondary: postoperative EVA-pain, analgesic consumption, length of stay.\n\nStudy Design Prospective, multicenter, parallel-group RCT (1:1 allocation, stratified by center\u002Fsex). Inclusion: consenting ASA I-II adults for abdominal surgery. Primary endpoint powered for 10mm EVA reduction (80% power, α=0.05). Registration supports PhD thesis at ISSS\u002FUniversité Hassan 1er Settat.",[87,88,89,90,91],"Hypnosis","Preoperative Anxiety","Postoperative Pain","Abdominal Surgeries","Length of Stay",[93,94,87,95],"RCT","Morocco","preoperative anxiety","2026-05-30",{"date":98,"type":36},"2026-06-02",{"date":100,"type":36},"2026-02-07",{"date":102,"type":21},"2026-06-03",{"name":104,"class":43},"HASSAN 1st university",3,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":79,"enrollmentInfo":115,"targetDuration":4,"studyType":82,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100638609","phase-3-alirocumab-for-stabilisation-of-symptomatic-vulnerable-carotid-plaque-100638609","NCT07586540","Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque","Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial With High-Resolution Vessel-Wall MRI and Clinical Endpoints","CAROTID-STABIL","Inclusion Criteria:\n\n1. Age ≥ 40 and ≤ 80 years\n2. Recently symptomatic (TIA, amaurosis fugax, or non-disabling ischaemic stroke with mRS ≤ 2) referable to a carotid territory within 28 days of randomisation\n3. Ipsilateral extracranial internal carotid artery stenosis of 50-69% by NASCET criteria on CTA or DSA\n4. HR-VW-MRI evidence of IPH (MPRAGE hyperintensity ≥150% of adjacent sternocleidomastoid) OR LRNC ≥ 10% of plaque volume in the symptomatic plaque\n5. On a stable dose of high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for ≥ 4 weeks, or able and willing to initiate atorvastatin 80 mg daily at randomisation\n6. LDL-C ≥ 70 mg\u002FdL (1.8 mmol\u002FL) at screening\n7. Able to undergo 3T MRI (no contraindications)\n8. Provides written informed consent\n\nExclusion Criteria:\n\n1. Indication for urgent carotid revascularisation within 14 days per treating team\n2. Disabling stroke (mRS \\> 2) or NIHSS \\> 5 at randomisation\n3. Carotid stenosis ≥ 70% or occlusion\n4. Cardioembolic stroke source (atrial fibrillation, LV thrombus, endocarditis, PFO with high-risk features)\n5. Intracranial haemorrhage within 12 months or any history of symptomatic ICH\n6. eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n7. Active hepatobiliary disease or ALT\u002FAST \\> 3x ULN\n8. Prior exposure to any PCSK9 inhibitor or inclisiran within 6 months\n9. Known hypersensitivity to alirocumab or excipients\n10. Pregnancy, breastfeeding, or unwillingness to use contraception in women of childbearing potential\n11. Life expectancy \\\u003C 24 months\n12. Participation in another interventional trial within 30 days\n13. Inability to comply with follow-up or MRI schedule","40 Years",{"count":116,"type":21},280,[118],"PHASE3","CAROTID-STABILISE is a phase III, multicentre, randomised, double-blind, placebo-controlled trial evaluating whether alirocumab 150 mg subcutaneously every 2 weeks, added to high-intensity statin therapy, produces greater reduction in intraplaque haemorrhage (IPH) volume at 26 weeks compared with placebo in patients with recently symptomatic carotid stenosis of 50-69% harbouring IPH or lipid-rich necrotic core (LRNC) on high-resolution vessel-wall MRI. The study will enroll 280 participants across multiple centres with a 52-week extension for durability and clinical endpoints assessment.",[121],"Carotid Stenosis",[123,124,125],"vulnerable plaque","alirocumab","PCSK9 inhibitor","NOT_YET_RECRUITING","2026-05-08",{"date":129,"type":36},"2026-05-14",{"date":131,"type":21},"2027-07",{"date":133,"type":21},"2030-09",{"name":135,"class":43},"Middle East North Africa Stroke and Interventional Neurotherapies Organization",14,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":82,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":136},"100635104","mena-regional-endovascular-intervention-for-venous-cerebral-venous-sinus-thrombosis-100635104","NCT07548346","MENA Regional Endovascular Intervention for Venous Cerebral Venous Sinus Thrombosis","REVIVE-CVST: A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint (PROBE) Trial of Endovascular Thrombectomy Plus Standard Medical Care Versus Standard Medical Care Alone in Adults With Acute or Subacute Cerebral Venous Sinus Thrombosis at High Risk of Poor Outcome in the Middle East and North Africa Region","REVIVE-CVST","Inclusion Criteria:\n\n* Age 18-65 years, inclusive\n* Radiologically confirmed cerebral venous sinus thrombosis (CVST) by CT venography (CTV), MR venography (MRV), or digital subtraction angiography (DSA), with thrombosis of at least one major dural sinus\n* Acute or subacute presentation with symptom onset within 21 days of randomization\n* MRI phase characterization confirming acute or subacute phase\n* At least one risk factor for poor outcome: symptoms of intracranial hypertension (severe headache, papilledema, visual obscurations), focal neurological deficit, seizures, altered consciousness (GCS 9-14), intracranial hemorrhage from venous congestion, or deep venous system thrombosis\n* Significant venous outflow obstruction on imaging\n* Written informed consent from patient or legally authorized representative\n\nExclusion Criteria:\n\n* Isolated cortical vein thrombosis without dural sinus involvement\n* Isolated cavernous sinus thrombosis\n* Chronic-phase CVST on MRI phase characterization\n* Pre-morbid modified Rankin Scale (mRS) score greater than 2\n* Glasgow Coma Scale (GCS) score less than 9 at randomization\n* Imminent risk of transtentorial herniation requiring emergent decompressive craniectomy\n* Massive cerebral edema with midline shift greater than 10 mm requiring surgical intervention\n* Active systemic bleeding or hemorrhagic diathesis\n* Severe allergy to iodinated contrast media\n* CVST secondary to active hematological malignancy or life expectancy less than 12 months\n* Pregnancy\n* Participation in another interventional clinical trial within 30 days\n* Any condition rendering the patient unsuitable for study participation per investigator judgment","65 Years",{"count":147,"type":21},440,[84],"REVIVE-CVST is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial evaluating whether early endovascular thrombectomy (EVT) combined with standard anticoagulation improves outcomes compared to anticoagulation alone in patients with severe cerebral venous sinus thrombosis (CVST).\n\nThe study targets adult patients (aged 18 years or older) presenting within 14 days of symptom onset with imaging-confirmed CVST and at least one severity marker, such as a Glasgow Coma Scale score of 14 or below, intracerebral hemorrhage, venous infarction, or deep venous system involvement.\n\nParticipants will be randomly assigned in a 1:1 ratio to either the intervention arm (EVT plus anticoagulation) or the control arm (anticoagulation alone). The primary endpoint is functional outcome at 180 days as measured by the modified Rankin Scale (mRS), using a shift analysis across all mRS categories.\n\nThe trial aims to enroll 440 participants across approximately 15 centers in the Middle East, North Africa, South Asia, and Turkey (MENA-SINO network). The study duration is approximately 42 months, including 18 months of enrollment and 12 months of follow-up for the last enrolled patient.",[151],"Cerebral Venous Sinus Thrombosis",[153,154,155],"CVST","endovascular thrombectomy","anticoagulation","2026-04-16",{"date":158,"type":36},"2026-04-23",{"date":160,"type":21},"2026-07",{"date":162,"type":21},"2030-01",{"name":135,"class":43},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":82,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":44},"100629885","pharmacogenetic-guided-antidepressant-treatment-in-depression-100629885","NCT07480486","Pharmacogenetic-Guided Antidepressant Treatment in Depression","Pharmacogenetic-Guided Antidepressant Treatment for Major Depressive Disorder: A Randomized Controlled Trial in Morocco","PGX-MDD","Inclusion Criteria:\n\n* Diagnosis of a depressive disorder (major depressive disorder, depressive episode, or persistent depressive disorder) confirmed by a healthcare professional according to DSM-5 or ICD-10 criteria.\n* Aged 18 years or older at the time of enrollment.\n* Clinical indication for initiation or modification of antidepressant pharmacotherapy.\n* Ability to understand study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Current acute psychotic disorder, manic episode, or uncontrolled bipolar disorder.\n* Current pregnancy or breastfeeding.\n* Use of medications with clinically significant interactions with antidepressants.\n* Any severe medical condition that, in the opinion of the investigator, would compromise participant safety or study integrity.",{"count":173,"type":21},570,[84],"The purpose of this clinical trial is to evaluate whether using pharmacogenetic testing to guide antidepressant treatment can improve outcomes in adults with major depressive disorder in Morocco. Depression is a common mental health condition, and finding the most effective antidepressant for a patient can take time. Some individuals do not respond well to the first medication prescribed or may experience side effects.\n\nPharmacogenetic testing examines genetic variations that can influence how a person processes certain medications. Information about genes involved in drug metabolism, such as CYP2D6 and CYP2C19, may help clinicians choose antidepressants and adjust doses more appropriately for each patient.\n\nThe main question this study aims to answer is whether treatment guided by pharmacogenetic test results leads to higher remission rates of depressive symptoms compared with usual clinical care.\n\nIn this study, participants diagnosed with major depressive disorder will be randomly assigned to one of two groups. In the pharmacogenetic-guided group, clinicians will receive the patient's genetic test results and may use this information to guide antidepressant selection and dosing. In the usual care group, antidepressant treatment will be prescribed according to standard clinical practice without access to pharmacogenetic information.\n\nParticipants will receive antidepressant treatment and will be followed for 12 weeks. During this period, depressive symptoms will be evaluated using standardized clinical questionnaires, including the Patient Health Questionnaire (PHQ-9). Information on treatment response, medication tolerance, and adverse effects will also be collected.\n\nThis study aims to provide evidence on the potential role of pharmacogenetic-guided treatment in improving depression management and to support the development of personalized medicine approaches in psychiatric care in Morocco.",[177],"Depression - Major Depressive Disorder",[179,180,181,182,183,184,185],"Pharmacogenetics","Pharmacogenomics","Antidepressant Treatment","Precision Medicine","Major Depressive Disorder","Depression","Personalized Medicine","2026-04-04",{"date":188,"type":36},"2026-04-09",{"date":190,"type":21},"2026-04-01",{"date":192,"type":21},"2027-05-01",{"name":194,"class":43},"Mohammed V University in Rabat",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":105},"100600345","the-pvco2-paco2cao2-cvo2-ratio-in-septic-shock-100600345","NCT07096284","The PvCO2-PaCO2\u002FCaO2-CvO2 Ratio in Septic Shock","Prognostic Value and Kinetics of the PvCO2-PaCO2\u002FCaO2-CvO2 Ratio Compared to Arterial Lactate in the Initial Phase of Septic Shock","SepsisO2CO2R","Inclusion Criteria:\n\nPatients aged over 18 years presenting with septic shock, defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and lactatemia \\> 2 mmol\u002FL despite adequate fluid resuscitation. Sepsis is defined by the presence of a suspected or confirmed infectious source associated with organ dysfunction (neurological, respiratory, renal, hepatic, or hematological). \\[Sepsis 3 criteria\\]\n\nExclusion Criteria:\n\n* Absence of central venous access.\n* Central venous access not positioned in the superior vena cava (e.g., femoral access).",{"count":204,"type":21},30,"The ratio of the venous-arterial carbon dioxide partial pressure difference to the arteriovenous oxygen content difference (Pv-aCO₂\u002FCa-vO₂) may be a marker of anaerobic metabolism in patients with acute circulatory failure. This study aims to assess the prognostic value of the PvCO2-PaCO2\u002FCaO2-CvO2 in the early phase of septic shock.",[207],"Septic Shock",[209,210],"sepsis","anaerobic metabolism","2026-03-28",{"date":213,"type":36},"2026-03-31",{"date":215,"type":36},"2025-01-05",{"date":217,"type":21},"2026-06-30",{"name":219,"class":43},"Avicenna Military Hospital",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":228,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":82,"phases":232,"briefSummary":234,"conditions":235,"keywords":240,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":44},"100628352","phase-4-tranexamic-acid-for-bleeding-reduction-during-turp-surgery-100628352","NCT07460518","Tranexamic Acid for Bleeding Reduction During TURP Surgery","Tranexamic Acid for Perioperative Haemostatic Optimisation During Transurethral Resection of the Prostate: A Randomized Quadruple-Blind Placebo-Controlled Trial","TXA-TURP","Inclusion Criteria:\n\n* Male patients aged 50 years or older\n* Diagnosed with benign prostatic hyperplasia (BPH)\n* Scheduled for elective transurethral resection of the prostate (TURP) under spinal anesthesia\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Provided written informed consent\n\nExclusion Criteria:\n\n* History of thromboembolic disease (deep vein thrombosis, pulmonary embolism, stroke)\n* Known hypersensitivity to tranexamic acid\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Coagulation disorders\n* Current anticoagulant therapy not appropriately discontinued\n* History of seizure disorder\n* Refusal to participate","MALE","50 Years",{"count":231,"type":21},80,[233],"PHASE4","Transurethral resection of the prostate (TURP) is commonly performed in elderly patients and may be associated with perioperative bleeding leading to postoperative anemia and delayed recovery. Tranexamic acid (TXA), an antifibrinolytic agent, may reduce surgical bleeding by inhibiting fibrin degradation.\n\nThis prospective randomized quadruple-blind placebo-controlled clinical trial evaluates whether perioperative administration of intravenous tranexamic acid reduces intraoperative blood loss and preserves postoperative hemoglobin concentration in patients undergoing TURP under standardized spinal anesthesia.\n\nParticipants are randomly assigned to receive either intravenous tranexamic acid or placebo prior to surgery. The primary outcomes assess objective measures of perioperative blood loss and postoperative hemoglobin levels. Secondary outcomes include recovery parameters, perioperative safety, and exploratory hospital-level economic impact.\n\nThe study aims to determine whether anesthesia-led haemostatic optimization using tranexamic acid improves perioperative physiological stability and recovery efficiency within an enhanced recovery framework.",[236,237,238,239],"Benign Prostatic Hyperplasia","Transurethral Resection of the Prostate","Perioperative Bleeding","Anemia, Postoperative",[241,242,243,244,245,246,247,248],"Tranexamic Acid","TURP","Patient Blood Management","Spinal Anesthesia","Randomized Controlled Trial","Hemostasis","Enhanced Recovery After Surgery","Perioperative Medicine","2026-03-05",{"date":251,"type":36},"2026-03-10",{"date":253,"type":21},"2026-03-15",{"date":255,"type":21},"2026-09-01",{"name":257,"class":43},"Hamza Najout",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":265,"minAge":18,"maxAge":145,"enrollmentInfo":266,"targetDuration":4,"studyType":82,"phases":268,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":44},"100618873","posturography-rehabilitation-and-pelvic-floor-training-on-urinary-incontinence-in-women-100618873","NCT07337278","Posturography Rehabilitation and Pelvic Floor Training on Urinary Incontinence in Women","Effect of Lumbopelvic Rehabilitation Using Posturography Combined With Pelvic Floor Training on Urinary Incontinence in Women","Inclusion Criteria:\n\n* Female participants aged between 18 and 65 years\n* Presence of clinical signs of urinary incontinence (stress urinary incontinence and\u002For urge urinary incontinence and\u002For mixed urinary incontinence) diagnosed according to the International Continence Society (ICS) terminology\n* USP (urinary symptom profile) scores for stress urinary incontinence and\u002For overactive bladder ≥ 1\n* Normal neuro-perineal examination\n* Written informed consent provided prior to participation in the study\n\nExclusion Criteria:\n\n* Known detrusor overactivity or reduced bladder compliance of neurological origin\n* Associated voiding dysfunction, defined as a Urinary Symptom Profile (USP) dysuria subscale score ≥ 1\n* Known organic or morphological pathology of the lower urinary tract\n* Pelvic organ prolapse grade II or higher according to the Pelvic Organ Prolapse Quantification system (POP-Q)\n* Current urinary tract infection or vaginal infection\n* Cognitive or visual impairments that may interfere with understanding or performing the exercise program\n* Pregnant women or women within 10 months postpartum\n* Anticholinergic medication use or hormone replacement therapy within the last 6 months\n* Recent pelvic or abdominal surgery within the last 6 months","FEMALE",{"count":267,"type":21},78,[84],"The goal of this clinical trial is to evaluate whether lumbopelvic postural rehabilitation combined with pelvic floor muscle training (PFMT) is more effective than PFMT alone in women with urinary incontinence. The main questions it aims to answer are:\n\n* Does the addition of lumbopelvic postural rehabilitation improve the severity of urinary incontinence as measured by the ICIQ-UI-SF questionnaire?\n* Does it improve urinary symptom profile, pelvic floor muscle strength, patient-reported overall improvement, and quality of life compared to PFMT alone?\n\nParticipants will be randomly assigned to one of two groups:\n\n* Experimental group (Group A): PFMT (3 sessions\u002Fweek) plus lumbopelvic postural rehabilitation (2 sessions\u002Fweek) for 12 weeks.\n* Control group (Group B): PFMT alone (3 sessions\u002Fweek) for 12 weeks. Participants will perform pelvic floor exercises in supine and seated positions, with supervised sessions at the hospital and home exercises. Postural rehabilitation includes stability and mobility exercises for the lumbopelvic region using Posturography. Outcomes will be assessed at baseline, at 6 weeks, and at 12 weeks.",[271],"Urinary Incontinence",[273],"Urinary incontinence, Pelvic floor, Lumbopelvic static, Posturography","2026-01-01",{"date":276,"type":36},"2026-01-13",{"date":278,"type":36},"2025-11-20",{"date":280,"type":21},"2026-03",{"name":194,"class":43},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":82,"phases":292,"briefSummary":294,"conditions":295,"keywords":298,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":5},"100407053","phase-2-safety--efficacy-of-dcr-phxc-in-patients-with-ph1-and-esrd-100407053","NCT04580420","Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD","A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis","PHYOX7","Note: Currently, the DCR-PHXC-204 study is only enrolling potential participants under 6 years of age.\n\nInclusion Criteria:\n\n1. Four age groups of participants will be enrolled:\n\n   1. adults and adolescents (aged ≥ 12 years)\n   2. children 6 to 11 years of age\n   3. children 2 to 5 years of age\n   4. infants and newborns from birth to \\\u003C 2 years of age\n2. . Documented diagnosis of PH1, confirmed by genotyping\n3. Estimated GFR at Screening \\\u003C30mL\u002Fmin normalized to 1.73m\\^2 BSA\n4. Mean of 2 Plasma Oxalate \\>20μmol\u002FL during screening\n5. For participants receiving hemodialysis or peritoneal dialysis total duration of hemodialysis or peritoneal dialysis must be less than 24 months and hemodialysis or peritoneal dialysis regimen must have been stable for at least 2 weeks prior to Screening.\n6. Male or Female\n\n   1. Male participants:\n\n      * A male participant with a female partner of childbearing potential must agree to use contraception during the treatment period and for at least 12 weeks after the last dose of study intervention and refrain from donating sperm during this period.\n   2. Female participants:\n\n      * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n      Not a woman of childbearing potential (WOCBP).\n      * OR\n      * A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 12 weeks after the last dose of study intervention and agrees to refrain from harvesting\u002Ffreezing eggs during this period.\n   3. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n7. Participant (and\u002For participant's parent or legal guardian if participant is a minor \\[defined as patient \\\u003C18 years of age, or younger than the age of majority according to local regulations\\]) is capable of giving signed informed consent, which includes compliance with the requirement and restrictions listed in the informed consent form (ICF) and in the protocol.\n\n   1. Adolescents (12 to \\\u003C 18 years of age, or older than 12 years but younger than the age of majority according to local regulations) must be able to provide written assent for participation.\n   2. For children younger than 12 years of age, assent will be based on local regulations\n8. Affiliated with or is a beneficiary of a health insurance system (if applicable per national regulations)\n\nExclusion Criteria:\n\n1. Prior hepatic transplantation; or scheduled transplantation within 6 months of Day 1. Prior renal transplantation is allowed.\n2. Documented evidence of clinical manifestations of severe systemic oxalosis (including preexisting retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations)\n3. Presence of any condition or comorbidities that would interfere with study compliance or data interpretation or potentially impact patient safety including, but not restricted to:\n\n   1. Severe intercurrent illness\n   2. Known causes of active liver disease\u002Finjury (e.g., alcoholic liver disease, nonalcoholic fatty liver disease\u002Fsteatohepatitis)\n   3. Non-PH related conditions contributing to renal insufficiency\n   4. Physician concerns about intake of drugs of abuse or excessive alcohol intake, or history of excessive alcohol intake in the 2 years prior to enrollment (defined as ≥ 21 units of alcohol per week in men and ≥ 14 units of alcohol per week in women; where a \"unit\" of alcohol is equivalent to a 12-ounce beer, 4-ounce glass of wine, or 1ounce shot of hard liquor)\n4. Use of an RNAi drug, other DCR-PHXC, within the last 6 months\n5. History of one or more of the following reactions to an oligonucleotide-based therapy:\n\n   1. Severe thrombocytopenia (platelet count ≤ 100,000\u002FµL)\n   2. Hepatotoxicity, defined as alanine transaminase (ALT) or aspartate transaminase (AST) \\> 3 times the upper limit of normal (ULN) and total bilirubin \\> 2 × ULN or international normalized ratio (INR) \\>1.5\n   3. Severe flu-like symptoms leading to discontinuation of therapy\n   4. Localized skin reaction from the injection (graded severe) leading to discontinuation of therapy\n   5. Coagulopathy\u002Fclinically significant prolongation of clotting time\n6. Participation in any clinical study in which they received an investigational medicinal product (IMP) other than DCR-PHXC within 4 months before Screening.\n7. Liver function test abnormalities: ALT and\u002For AST \\>1.5 × ULN for age and gender\n8. Positive anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibody test at Screening\n9. Known hypersensitivity to DCR-PHXC or any of its ingredients\n10. Inability or unwillingness to comply with the specified study procedures, including the lifestyle considerations",{"count":291,"type":21},28,[293],"PHASE2","The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.",[296,297],"Primary Hyperoxaluria Type 1","End Stage Renal Disease",[299,300],"PH1","ESRD","2025-12-23",{"date":303,"type":36},"2025-12-24",{"date":305,"type":36},"2021-04-15",{"date":307,"type":21},"2032-01-30",{"name":309,"class":69},"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":316,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":330},"100615617","study-protocol-10-year-follow-up-of-patients-screened-for-cardiovascular-risk-by-the-all-with-heart-association---development-of-a-morocco-specific-risk-score-100615617","NCT07294937","Study Protocol: 10-Year Follow-Up of Patients Screened for Cardiovascular Risk by the \"All With Heart\" Association - Development of a Morocco-Specific Risk Score","Inclusion Criteria:\n\n* Adults aged 40 years or older at the time of the initial screening (2010-2012).\n* Individuals who participated in the cardiovascular risk screening campaign conducted by the \"All with heart\" Association between 2010 and 2012 in the Greater Casablanca region.\n* Moroccan nationality.\n* Participants or family members who provide written informed consent for participation in the 10-year follow-up study.\n\nExclusion Criteria:\n\n* Individuals who refuse to participate in the follow-up study.\n* Participants who have moved and cannot be reached by phone, WhatsApp, or SMS.\n* Participants who died from non-cardiovascular causes.\n* Non-Moroccan participants.",{"count":317,"type":21},10000,"Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and their prevalence is steadily increasing in Morocco. Between 2010 and 2012, the \"All with heart\" Association conducted a large-scale cardiovascular screening campaign in the Greater Casablanca region, involving more than 10,000 adults aged over 40 years. This 10-year follow-up study aims to evaluate long-term cardiovascular outcomes and to develop a Morocco-specific cardiovascular risk score. Follow-up data will be collected through phone calls, WhatsApp, or SMS with participants or their families to document cardiovascular deaths, myocardial infarctions, and strokes. Statistical analyses, including survival analysis and multivariate logistic regression, will be used to identify significant risk factors and to construct a predictive risk model tailored to the Moroccan population. The study received a favorable opinion from the Rabat Ethics Committee. Written informed consent will be obtained from all participants or their families prior to data collection. The findings are expected to enhance understanding of cardiovascular risk evolution in Morocco and to provide a validated, population-specific risk score to support prevention and patient management strategies.",[320],"Cardiovascular Diseases (CVD)","2025-12-15",{"date":323,"type":36},"2025-12-19",{"date":325,"type":36},"2025-10-01",{"date":327,"type":21},"2026-10",{"name":329,"class":43},"Moroccan Society of Cardiology",2,{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":339,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":82,"phases":343,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":44},"100612626","indispensable-amino-acids-bioavailability-in-children-with-environmental-enteropathy-dysfunction-iaa-eed-100612626","NCT07256028","Indispensable Amino Acids Bioavailability in Children With Environmental Enteropathy Dysfunction (IAA-EED)","Use of Stable Isotopic Dilution to Assess the Bioavailability of Indispensable Amino Acids in Children With Environmental Enteropathy Dysfunction (IAA-EED)","IAA-EED","Inclusion Criteria:\n\n* Stunting estimated at least - 2 z score height -for-age\n* Abnormal intestinal morphology on jejunal biopsy showing features for EED:\n* mucosal inflammation,\n* villous blunting\n* altered barrier integrity\n\nExclusion Criteria:\n\n* Celiac disease\n* Presence of anti-tissue transglutaminase antibodies.\n* Primary immunodeficiency disorders\n* Inflammatory bowel disease\n* Intestinal inflammation food allergy","18 Months","36 Months",{"count":342,"type":21},40,[84],"In Morocco, large efforts have been made to enhance nutritional status and health conditions of children. Accordingly, stunting was reduced and the prevalence of stunting have decreased from 28,6% in 1987 to 14,9% in 2011. Many factors, including improved nutrition, have influenced this decrease, and are reinforced to maintain this low prevalence of stunting. Of interest, quality diet, specifically with reference to its protein quality, has contributed to improve the nutritional status of the Moroccan population. However, infectious diseases are still important and in some areas many children are of high risk to develop EED that alter intestinal permeability and microbial translocation, and lead to systemic inflammation. During childhood, protein supply is of a great interest and indigestibility of these proteins and\u002For malabsorption of indispensable amino acids will affect children growth and many physiological and cognitive functions. This project was planned to assess indispensable amino acids during EED and to to assess the impact of some interventions (amino acids supplementation \u002F medical treatment) on the nutritional status of children.\n\nThis study will be carried out according to a trilogy of close collaboration between CNESTEN, Pr Claire Gaudichon from AgroParisTech (France) who will provide technical assistance and scientific accompaniment during the progress of the project, she will also participate in the data analysis, exploitation and valorization of results and the department of Pediatric Hepatology Gastroenterology and Nutrition-P III at the Children's Hospital in Rabat.",[346],"Environmental Enteric Dysfunction",[348,349,350,351],"Indispensable amino acids","Environmental enteric dysfunction","bioavailability","amino acids supplementatuion","2025-11-27",{"date":354,"type":36},"2025-12-01",{"date":356,"type":21},"2025-12-10",{"date":358,"type":21},"2026-07-31",{"name":360,"class":43},"Morocco's National Centre for Energy, Sciences and Nuclear Techniques",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":370,"studyType":23,"phases":4,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":383},"100272903","computerized-registry-of-patients-with-venous-thromboembolism-riete-100272903","NCT02832245","Computerized Registry of Patients With Venous Thromboembolism (RIETE)","RIETE","Inclusion Criteria:\n\n* Confirmed VTE (acute deep-vein thrombosis, pulmonary embolism and\u002For superficial venous thrombosis) by objective tests.\n* Informed consent to the participation in the study, according to the requirements of the ethics committee within each hospital.\n\nExclusion Criteria:\n\n* Participation in a therapeutic clinical trial with an unknown drug.\n* Inability to the 3 month follow-up",{"count":369,"type":21},120000,"3 Years","The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism.\n\nThe main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy, extreme body weight, etc), with the purpose of decreasing mortality, frequency of thromboembolic recurrences as well as bleeding complications and arterial events.\n\nAs an additional objective RIETE is also aimed to create predictive scores that help physicians to better identify patients with high risk of presenting some of these complications.\n\nThe primary parameters recorded by the registry comprise details of each patient's clinical status, including any coexisting or underlying conditions, and the type, dose, duration and outcome (during the first 3 months of therapy) of antithrombotic treatment. Study endpoints are clinically recognized (and objectively confirmed) recurrences of VTE, major and minor bleeding complications, and death.",[373],"Venous Thromboembolism","2025-09-23",{"date":376,"type":36},"2025-09-24",{"date":378,"type":4},"2001-03",{"date":380,"type":21},"2027-12",{"name":382,"class":43},"Manuel Monreal",257,{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":265,"minAge":18,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":82,"phases":395,"briefSummary":396,"conditions":397,"keywords":400,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":330},"100535189","phase-4-continuous-infusion-of-norepinephrine-vs-phenylephrine-during-spinal-anesthesia-for-cesarean-section-inpeace-100535189","NCT06248593","Continuous Infusion of Norepinephrine vs Phenylephrine During Spinal Anesthesia for Cesarean Section (INPEACE)","Manually Controlled Continuous Infusion of Norepinephrine vs Phenylephrine During Spinal Anesthesia for Cesarean Section: A Double-blinded Randomized Controlled Study","INPEACE","Inclusion Criteria:\n\n* Full-term, singleton, pregnant women, nonlaboring.\n* Scheduled for elective cesarean delivery under spinal anesthesia,\n* American Society of Anesthesiologists physical status : 1 or 2\n* Baseline systolic BP between 90 and 140 mm Hg.\n\nExclusion Criteria:\n\n* Known fetal abnormality.\n* Preexisting or pregnancy-induced hypertension, cardiovascular, cerebrovascular or kidney disease.\n* Contraindication to spinal anesthesia.\n* Peripartum hemorrhage.\n* Body mass index above 40 kg\u002Fm2.","45 Years",{"count":394,"type":21},140,[233],"The goal of this clinical trial is to compare norepinephrine and ephedrine in maintaining blood pressure during spinal anaesthesia for elective cesarean delivery. The main questions it aims to answer are:\n\n* Do phenylephrine and norepinephrine administered as manually controlled continuous infusion during elective cesarean delivery have different effects on neonatal outcome ?\n* Do phenylephrine and norepinephrine administered as manually controlled continuous infusion during elective cesarean delivery have different effects on maternal hemodynamics? Participants will receive either phenylephrine or norepinephrine infusion, at the time of performing spinal anesthesia, the infusion rate will be adjusted manually depending on maternal arterial pressure.",[398,399],"Cesarean Section Complications","Hypotension",[401,402,403,404,405,406],"hypotension","norepinephrine","cesarean delivery","Obstetric anesthesia","Spinal anesthesia","Phenylephrine","2025-09-08",{"date":409,"type":36},"2025-09-09",{"date":411,"type":36},"2025-01-29",{"date":253,"type":21},{"name":414,"class":43},"Hassan II University",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":82,"phases":424,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":44},"100574989","effectiveness-of-instrumental-rehabilitation-in-patients-with-adhesive-capsulitis-100574989","NCT06766448","Effectiveness of Instrumental Rehabilitation in Patients With Adhesive Capsulitis","Robotic Training in the Management of Adhesive Capsulitis: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients \\>18 years of age\n* Shoulder pain and\u002For movement limitation\n* Idiopathic AC or associated with confirmed systemic disease (e.g., diabetes or dyslipidemia)\n\nExclusion Criteria:\n\n* Cognitive impairment\n* History of surgery\n* Fracture or dislocation of the shoulder\n* History of shoulder tendinopathy\n* History of inflammatory or degenerative disease\n* Infection\n* Neurological disease (Parkinson's disease, stroke, multiple sclerosis, neurological\n* Manipulation under anesthesia, hydro dilation, platelet rich plasma or hyaluronic acid infiltration within the last 6 months",{"count":423,"type":21},70,[84],"The aim of this study is to evaluate the effectiveness of robotic training compared to conventional rehabilitation in patients with AC.",[427],"Adhesive Capsulitis of the Shoulder",[429,430,431],"adhesive capsulitis","rehabilitation","robotic training","2025-01-30",{"date":434,"type":36},"2025-02-03",{"date":436,"type":36},"2021-03-23",{"date":438,"type":21},"2025-04",{"name":440,"class":43},"Mohammed V Souissi University",{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":447,"targetDuration":448,"studyType":23,"phases":4,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":460},"100575206","hypertension-registry-study-of-primary-and-secondary-hypertension-phenotypes-complications-and-treatment-personalization-100575206","NCT06769269","Hypertension Registry: Study of Primary and Secondary Hypertension Phenotypes, Complications, and Treatment Personalization.","Inclusion Criteria:\n\n* Individuals aged over 18 years.\n* Patients with blood pressure:\n\n  * Higher than 140 mmHg systolic and\u002For higher or equal to 90 mmHg diastolic in consultation or in a hospital setting.\n  * Higher than 135\u002F85 mmHg at home or in ambulatory blood pressure measurements (ABPM).\n* Patients who have agreed and signed the informed consent.\n* Patients with legal status in the Moroccan kingdom.\n\nExclusion Criteria:\n\n* Patient without diagnosis of hypertension\n* Patient under 18 years old\n* Patients refusing to sign the informed consent.\n* Patients with illegal status in the kingdom.",{"count":317,"type":21},"1 Year","The quality of primary healthcare systems for patients with hypertension (HTA) in Morocco is a critical issue due to its high prevalence and significant impact on morbidity and mortality. The concept of \"quality in primary care\" encompasses fundamental aspects such as timeliness, accessibility, and the provision of care based on current clinical guidelines and recommendations from professional societies.\n\nThis observational study on hypertension (HTA) uses an electronic registry accessible remotely to collect medical data from primary care and hospital settings. Investigators will be trained to ensure standardization in blood pressure measurements to minimize errors. The registry will include clinical, therapeutic, and complication data for patients aged 18 and over with a confirmed diagnosis of HTA, with information transmitted anonymously via a certified secure channel.\n\nInformed consent from patients will be required for including their data in the registry. Collected data will include anthropometric measurements (weight, height, waist circumference, body mass index), blood pressure measurements by validated devices or ambulatory measurements, and metabolic assessments (blood glucose, total cholesterol, triglycerides, LDL, HDL, urea, creatinine, uric acid, urine albumin-to-creatinine ratio). Cardiovascular complications will also be recorded.\n\nThe study design is a cohort study with a cross-sectional perspective and a targeted follow-up period of one year. The study aims to evaluate the prevalence and phenotypes of HTA in Morocco, as well as the geographic distribution of the disease. It will compare current data with those from previous years and other North African countries to assess the applicability of Moroccan clinical practices and recommendations from the European Society of Cardiology (ESC). The goal is to enhance the understanding and management of HTA, as well as to optimize prevention and treatment strategies.\n\nThis comprehensive analysis will help identify potential gaps in primary care and develop strategies to improve the management of hypertensive patients. The comparative evaluation of data related to examinations, treatments, and complications of the cohort of patients followed for hypertension during the period 2024-2026, in comparison with results from previous years and other countries, will provide valuable insights into the shortcomings and progress in care delivery. This approach will not only identify areas needing improvement but also highlight significant advances in hypertension management.",[451],"Arterial Hypertension","2025-01-23",{"date":454,"type":36},"2025-01-24",{"date":456,"type":36},"2025-01-21",{"date":458,"type":21},"2027-01-21",{"name":329,"class":43},5,{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":17,"minAge":467,"maxAge":468,"enrollmentInfo":469,"targetDuration":4,"studyType":82,"phases":471,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":460},"100436452","empowering-adolescents-to-lead-change-using-health-data-100436452","NCT04963426","Empowering Adolescents to Lead Change Using Health Data","Inclusion Criteria:\n\n* School going\n* Aged 13-17 years\n\nExclusion Criteria:\n\n* Not going to school\n* Outside the age range 13-17 years","13 Years","17 Years",{"count":470,"type":21},12612,[84],"This study is a cluster randomized trial carried out in schools of secondary cities of four low- and middle income countries. Baseline surveys in 30 randomly selected schools will assess the health behaviours of 13-17 year old students as well as school policies and practices. The intervention arm (15 schools) will use the baseline information to develop a package of actions in collaboration with students, teachers, and local authorities that will subsequently be implemented an monitored over two years. Follow-up surveys to evaluate the effectiveness of the implemented actions will be conducted after two years in all 30 previously selected schools.",[474],"Healthy",[476,477,478,479,480,481],"adolescent health","students","schools","risk factors","protective factors","school health services","2024-08-06",{"date":484,"type":36},"2024-08-07",{"date":486,"type":36},"2022-01-01",{"date":488,"type":21},"2027-01",{"name":490,"class":43},"World Health Organization",{"id":492,"slug":493,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":497,"sex":17,"minAge":370,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":82,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":44},"100554294","smartphone-based-neurobehavioral-assessments-as-a-diagnostic-aid-in-autism-100554294","NCT06497218","Smartphone-Based Neurobehavioral Assessments as a Diagnostic Aid in Autism","Inclusion Criteria:\n\n* Male or female individuals between the ages of 3 - 12 years old at the time of consent.\n* Caregiver must be able to read, understand and sign the Informed Consent Form (ICF).\n* Normal or corrected-to-normal vision with visual acuity sufficient to watch short videos.\n* Hearing adequate to hear the auditory stimuli delivered via headphones.\n\nExclusion Criteria:\n\n* Participants under 3 or over 12 years old.\n* Severe hearing or visual impairment.\n* Participants using medication that affects the nervous system (classified as ATC N0 medication, https:\u002F\u002Fwww.whocc.no).",true,"12 Years",{"count":500,"type":21},450,[84],"Retrospective case-control study to assess the diagnostic accuracy in autism spectrum disorder (ASD) of a new smartphone-based platform designed to conduct neurometric evaluations by measuring facial and behavioural reflexes.",[504],"Autism Spectrum Disorder","2024-07-10",{"date":507,"type":36},"2024-07-12",{"date":509,"type":36},"2023-05-15",{"date":511,"type":21},"2025-01-15",{"name":513,"class":69},"Blinklab Limited",""]